Cenedella.de

Patient Advocate since 1977.


Leave a comment

Tommy Chong rumored to be re-appearing at ICBC Berlin

ICBC Berlin - The BERLIN PEACE ACCORDS...putting an end to the world war on Cannabis!

ICBC BERLIN will be held April 12-13, 2018 in Berlin Germany.

Tommy Chong and his CHONGS CHOICE offerings http://chongschoice.us/ were well-received by the international cannabis executives this year and rumor has it he will be there again in 2018.

For more information on this HIGHLY RECOMMENDED event, please go to:

http://internationalcbc.com/berlin-home/


Leave a comment

Commentary about Western Europe – by Ben Ward CEO of Maricann – on CNBC

Forget the US. Here’s where medical marijuana is really taking off

  • There is a global shift in cannabis towards Western Europe.
  • That’s where the action in medical marijuana is really heating up.
  • Investor’s focused solely on the U.S. are missing the huge potential overseas.
Benjamin Ward, CEO of Maricann Group Inc.
58684301

David McNew | Getty Images

There’s a groundswell of support for cannabis legalisation in the United States, with 29 states, as well as Washington D.C. approved for medicinal cannabis, and eight for lifestyle use.

Things are farther ahead in Canada. Regulations for production and sales have been in place for over three years, and the federal government has introduced a timeline to full federal legalisation for lifestyle use in July 2018. Capacity in Canada for lifestyle alone is projected to reach “5 billion dollars per year to start,” according to a recent report from Deloitte.

Yet, while many investors focus on opportunities stemming from Canada’s upcoming legalization – plus the longer-term investment potential in what will likely be a growing number of American states – they are missing the global shift in cannabis towards Western Europe. That’s where the action is really heating up.

The population of the United States is approximately 325 million. There are 35 million living in Canada. But compare that to the European Union’s population of 510 million. Germany, with more than 80 million people alone, legalized medicinal cannabis in January of this year. Add that to Italy’s nascent existing medicinal cannabis program.

“European markets are increasingly important to the cannabis sector. Each has a well-funded medical system, residents who seek natural and complementary therapies, and a government-supported mandate to stop the rising tide of opiate addiction related to chronic pain treatment.”

These European markets are increasingly important to the cannabis sector. Each has a well-funded medical system, residents who seek natural and complementary therapies, and a government-supported mandate to stop the rising tide of opiate addiction related to chronic pain treatment.

Taken together, these and other European examples show that we’re seeing traditionally conservative attitudes shift as medicinal cannabis is legalized.

That also means investors in cannabis who focus solely on North America are missing the huge potential found across the Atlantic.

Those investors restricting their cannabis investments to this side of the ocean – and in the United States in particular – are left navigating an array of legislation on a state-by-state basis, prohibitive out-of-state investment regulations, and a prohibitive tax code. These investors miss the boat as they churn through such choppy water.

In Germany, cannabis will be produced by licenced producers and distributed to pharmacies like any other medication, with each prescription eligible for full reimbursement from health insurance.

In their patient-driven markets, Germans, Italians and other Europeans are demanding the alternative of cannabis over opiates.

In our view, people who think opiates are the only answer to pain relief have a similar mis-perception as people who still think medicinal cannabis is nothing more than smoking up with their doctor’s permission.

They are both wrong.

In short, medical cannabis is about personalized and effective medicine. It’s not about getting high.

The Europeans know that, as we do in North America.

As Germany moves smartly down this path of medicinal cannabis, the rest of Europe will soon follow. And to ignore 500 million people in a stable economy is a mistake.

We’re at the start of the global revolution. We all need to be looking to Europe next.

Commentary by Benjamin Ward, CEO of Maricann Group Inc., a vertically-integrated greenhouse producer and distributor of medical cannabis. Toronto, Canada-based Maricann is now building global teams in rapidly expanding European markets as well.

For more insight from CNBC contributors, follow @CNBCopinion on Twitter.


Leave a comment

The State of Cannabusiness in Germany

The State of Cannabusiness in Germany

As a cannabis business executive, you undoubtedly have been following some of the significant events happening in Europe and you have asked yourself: “How does this affect my plans?”

It may be the German government establishing a nationwide medical marijuana program, or news about the Canadian companies buying or merging with their European counterparts that has your attention. But you know the times are a changin’ and you might want to benefit from this historic moment in our Industry.

For those companies that already have a strategic international plan in place, the opportunities are boundless.  Germany, a nation with 2.5 times the population of California, is leading the way with the a national, Federal-government approved, medical marijuana law already in place, and numerous regional efforts to establish recreational use are getting off the ground as I write this column.

Having been an advocate in California during the medical marijuana legalization push of 1990s, and now living here in Germany as they build their own regulated marketplace, it has been fun to be involved. I’d now like to share some of the organizations that may be able to help you and your company, if Europe is indeed on your radar.

Das Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) is the German federal government’s  Institute for Drugs and Medical Devices and is lead by Professor Dr. Karl Broich. Their website is www.bfarm.de and they are basically the cannabis bureau of Germany, charged with implementing the medical marijuana law.  Interestingly, they will also be the sole purchaser of foreign-produced medical marijuana products, and then oversee the distribution exclusively though licensed pharmacies.

So Germans will be going to their local pharmacy to obtain their medicine, which officially should be paid by their insurance company.  Of course, the details are still being worked out, and I know of at least two lawsuits against insurance companies not paying for their clients medicine.

Last month, the BfArM put out a call for bids for the first ten authorized grow licenses in the history of Germany.  Negotiations are underway and the winning bidders should be announced shortly.  We will keep you updated on this, and all important details emanating from Europe, in future columns.

The Deutscher Hanfverband (DHV) is the German Hemp Association in Berlin and a fantastic resource and advocacy organization. They have been instrumental in getting the country to this point and their website is https://hanfverband.de I highly recommend signing up for their newsletter (which can easily be translated.)  Their next big event is the Hanf Parade in Berlin in August which will bring together over 10,000 advocates calling for open access.

For companies that want to get serious about being in Europe, the best organization I know of is the German Trade and Investment office located in Berlin which is part of the German Federal Ministry of Economic Affairs. Their website is www.gtai.de.

Their knowledge is vast, their connections incredible, and there is no charge for their services. They want to make it easy for international companies in our space to help Germany build their regulated marketplace. They provide advanced research, site-selection, tax information. And.. they are just an email or phone call away.

Of course, there are a total of 51 independent states that make up Europe and 28 of those make up the European Union.  To some degree all of these countries are changing the way they treat medical marijuana and CBD products.

If you are looking for some opportunities in this region, I would suggest looking not only at Germany, but also The Netherlands, Spain, United Kingdom, Switzerland, and the Czech Republic. Although Israel is not in the EU region, their expertise, leading edge research, products and capabilities are to be noted.

Before concluding, I need to give a shout out to Mr. Alex Rogers and his team at ICBC Berlin who put together one of the best industry events I have ever attended.  Back in April, in Berlin, almost 1000 attendees and exhibitors from throughout the world gathered to share information, make connections and close business deals.

Congressman Dana Rohrabacher, chairman of the Cannabis Caucus in the U.S. House of Representatives, was the keynote speaker and shared stories on his German ancestry, his first meeting with Ronald Reagan, and why legalizing our plant makes sense in so many ways.

Tommy Chong was also in attendance, was way coherent, and meeting him was definitely one of my personal highlights.  Yes, I admit it, I listened to his albums way back in 1971.

So I wish you a productive, successful and fun month ahead as we collectively take the next steps to “Make Cannabis Great Again” here in Europe, and wherever you are reading this in the world.

About The Author:


Leave a comment

There are significant opportunities for investors looking to profit from the expanding marijuana industry in other countries.

http://host.madison.com/business/investment/markets-and-stocks/forget-the-u-s-marijuana-market—-there/article_d7702424-c20b-5e1f-9987-70105d72cc8a.html

Marijuana stocks have soared as state after state in the U.S. has legalized marijuana for medical or recreational use. The market potential is huge, with some estimating that the marijuana industry in the U.S. could generate sales of more than $18 billion by 2020.

But focusing only on the U.S. is nearsighted — literally. There are significant opportunities for investors looking to profit from the expanding marijuana industry in other countries. Here are several important areas across the world with growing marijuana markets along with some of the marijuana stocks that could benefit from that growth.

Image source: Getty Images.

North America

Canada was the first North American country to legalize medical marijuana nationwide in 2001. Through the years, the Canadian medical marijuana market has grown but still stands at only $100 million or so. However, the market for medical marijuana in the country is projected to increase to roughly $900 million by 2020.

The bigger story for Canada is the prospect of legalization of recreational marijuana. Prime Minister Justin Trudeau is pushing for legislation that would legalize the drug for recreational use effective July 2018. However, there has been significant pushback that could derail the effort. If Trudeau succeeds, though, the Canadian marijuana market could increase to as much as $22.6 billion annually, according to research by international accounting and professional services firm Deloitte.

Mexico became the second North American country to legalize medical marijuana nationwide in June 2017. Legislation supporting legalization passed overwhelmingly in the Mexican congress. Recreational use of marijuana is still widely prohibited, although the government is considering the possibility of allowing Mexican citizens to legally possess up to one ounce of the drug.

How big could the Mexican marijuana industry be? It’s not likely to be nearly as large as either the U.S. or Canadian markets. However, Stuart Titus, CEO of Medical Marijuana, Inc. (NASDAQOTH: MJNA), thinks that Mexico could be an opportunity for cumulative revenue for his company alone over the next 10 years of $1 billion to $2 billion.

South America

In 2013, Uruguay became the first country in the world to fully legalize the sale and use of marijuana. As of July 2017, pharmacies in the South American nation will be allowed to sell marijuana over the counter.

While no other countries in South America have gone as far as Uruguay, several have relaxed marijuana laws in recent years. In 2015, both Chile and Colombia legalized medical use of marijuana or marijuana-based medications. Argentina approved medical use of marijuana in March of this year.

Brazil, which has the largest population of any country in South America by far, hasn’t legalized marijuana yet — although possession of small amounts of the drug has been decriminalized. There are signs that support for marijuana legalization is growing in Brazil, however, including a public statement by one of the country’s Supreme Court justices calling for legalization of marijuana.

The marijuana industry in South America remains relatively small at this point. Even in Uruguay, the industry has grown at a snail’s pace largely due to lack of funding for government agencies that oversee the marijuana market. Over time, however, it seems likely that the South American opportunity will become more significant.

Image source: Getty Images.


1 Comment

INTERNATIONAL CANNABIS AND CANNABINOIDS INSTITUTE – Warning to European CBD Consumers

https://www.marijuanatimes.org/icci-offers-warning-to-european-cbd-consumers/

ICCI-CBD-warning
Image Courtesy of Bill Griffin

Oils with a high CBD (cannabidiol) content have enjoyed a rise in popularity in the European market lately. As long as the THC content is no higher than 0.2% in most (but sadly, not all) European member states, CBD oil is perfectly legal.

Consumers are more aware of the medicinal properties of CBD and its non-psychotropic effect when ingested or inhaled.

This surge in awareness and demand has created a large – and unregulated – industry. Thanks to Europe’s free market, consumers are able to buy from another EU state with ease.

In Prague, under the framework of Patient Focus Certification (PFC), the world’s first independent testing took place of the quality of cannabidiol (CBD) products available on the retail market and the composition of “cannabis oils” available in the European Union. The results were found to be worrisome and highlighted the need for independent certification of the quality of mass-produced products made from cannabis.

Essentially, consumers only have the label and claims from the producer to go on when buying their CBD products. There is no way for them to test and validate these claims on their own. It is even difficult for the producers to get their products tested, so where this information is coming from is open to discussion.

In cooperation with the first European laboratory with a PFC certification – working within the Department of Food Analysis and Nutrition of the University of Chemistry and Technology, Prague (VŠCHT) – the International Institute for Cannabis and Cannabinoids (ICCI), also headquartered in Prague, assessed the quality of certain types of commercially available CBD oils on the European market.

Professor Jana Hajšlová, who led the testing, says, “For both categories, we are interested in the quality and authenticity of used oils and possible content of environmental contaminants, polycyclic aromatic hydrocarbons (PAH), which accumulate in oils (for protecting the health of their consumers, maximum limits have been anchored in legislation. For “CBD oils”, we also examined the consistency of the determined contents of CBD with the producer’s stated values and the potential content of THC.” THC, or tetrahydrocannabinol, is the main psychotropic substance found in cannabis that gets you high.

Professor Hajšlová and her team tested 29 oils containing the non-psychotropic biologically active substance from cannabis – CBD – and 25 oils from cannabis seeds purchased on the EU market in the last quarter of 2016.

Tomáš Zábranský, Director of Research at ICCI, explained why the following aspects were selected in the assessment of edible cannabis-based foods, “Multi-core polycyclic aromatic hydrocarbons, such as benzopryrene, are classified as carcinogens and genotoxic mutagens of class IIa – according to the classification of the International Agency for Research on Cancer (IARC). That means they are substances whose carcinogenicity was proven experimentally on animals, even though not on people (otherwise being prevented for ethical reasons), they have nevertheless been proven by a multitude of epidemiological studies. This especially pertains to ill persons trying to utilize the beneficial effects of CBD, but polycyclic aromatic hydrocarbons are unquestionably hazardous, mainly upon long-term (chronic) reception.”

In other words, what some people are buying to make them better could well have a detrimental effect on their health.

Another unexpected outcome of taking uncertified CBD products could be that you consume more THC than you were expecting. This could be seen as a nice problem for some, but potentially dangerous if the consumer is working in a hazardous environment, or even just doing a school or shopping run.

Tomáš explains, “Another problem is the excessive content of THC in the blood after use of CBD oils. THC is another medicinally active substance from cannabis, but it is psychoactive as opposed to CBD. Even its relatively low quantities can cause changes in perception among more sensitive individuals, which could jeopardize their ability to drive or make decisions in general – especially if they are not aware of the possibility of their psyche being influenced by an external substance.”

There could be legal implications for the consumer, too. “Another problem for drivers may be testing positive for THC upon traffic stops, which could lead at least to losing one’s driver’s license. Generally speaking, any psychoactive substance in one’s body about which one has no idea is always a problem.”

The results of their analysis exceeded expectations of the deficiencies in the claims of the producers. This lead ICCI, along with the Department of Food Analysis and Nutrition, to issue a warning to European consumers about the risks of hazardous contaminations.

They discovered that, in terms of the content of polyaromatic hydrocarbons (PAH), only 9 out of 29 (31%) of tested CBD oils were satisfactory.

Cannabis oils (which are actually oils from cannabis seeds and not from the plant) enjoyed better success in this basic food safety criterion. In this category, 23 out of 25 tested sample products (92%) satisfied the legal limits of PAH in foods.

The quality analysis also uncovered a problem in the lack of awareness of customers on the composition of the given product. A full 60% of tested CBD oils did not have any mention of the THC level on the label. This is important as consumers need to know if they exceed the recommended or maximum dosage of THC. Otherwise, they could end up testing positive for a THC level higher than the limit of 2ng per ml of blood upon screening during a traffic stop or employment.

For a quarter of the tested oils, the risk is affiliated with the use of a recommended dose and another 10% evoke this risk upon using the maximum dosage stated on the packaging. Further, labels of 34% of CBD oils showed discrepancies between the true content of CBD, or sums of CBD and cannabidiolic acid (CBDA), and the content stated by the producer.

This means that CBD consumers could not only be just plain old ripped off, they could be taking substances detrimental to their health, hazardous to their safety and psychological well-being, and  they could be unwittingly breaking the law whilst driving or lose their job after a drug test.

With the European hemp industry growing so much in recent years, ICCI’s study and other independent testing of the quality of cannabis-based products designed for human consumption highlight the need to introduce and observe standards for safe production and distribution.

Having met many people working within the industry over the last few years, I get the impression they are not trying to pull the wool over the eyes of innocent consumers, but rather they lack the knowledge to setup and manage facilities involved in the production and distribution of cannabis-related products. Up until now, there was no way for them to gain this knowledge.

Therefore last year, ICCI licensed the PFC program from the nonprofit American patient organization ASA (Americans for Safe Access) for certification outside the USA and localized the certification criteria for use in the EU.

Pavel Kubů, CEO of ICC,I explains what will happen with the results of this testing, “We are contacting all producers of the tested edible cannabis-based food products, we will share with them the results and offer assistance in checking the safety and increasing the quality of their products. The list of those foods that satisfied limits in the PAH analysis will be available to all consumers on the PFC International website. Members of patient organizations associated in the international association (IMCPC) will be provided information through the association KOPAC regarding the quality of the oil that they use and find out whether it was amongst those tested, and if so, with what results.”

US Attorney General Jeff Sessions – “How To Spot A Stoner”

Leave a comment